Gossamer Bio (GOSS) Competitors $2.08 +0.12 (+6.12%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$2.17 +0.09 (+4.33%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GOSS vs. ARQT, TARS, IMCR, SDGR, ADPT, EVO, JANX, EWTX, ABCL, and ANIPShould you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Immunocore (IMCR), Schrodinger (SDGR), Adaptive Biotechnologies (ADPT), Evotec (EVO), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), AbCellera Biologics (ABCL), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Gossamer Bio vs. Its Competitors Arcutis Biotherapeutics Tarsus Pharmaceuticals Immunocore Schrodinger Adaptive Biotechnologies Evotec Janux Therapeutics Edgewise Therapeutics AbCellera Biologics ANI Pharmaceuticals Gossamer Bio (NASDAQ:GOSS) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Is GOSS or ARQT more profitable? Gossamer Bio has a net margin of -41.12% compared to Arcutis Biotherapeutics' net margin of -60.95%. Arcutis Biotherapeutics' return on equity of -80.66% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer Bio-41.12% -128.98% -15.52% Arcutis Biotherapeutics -60.95%-80.66%-32.94% Do analysts prefer GOSS or ARQT? Gossamer Bio presently has a consensus price target of $8.25, indicating a potential upside of 296.63%. Arcutis Biotherapeutics has a consensus price target of $19.40, indicating a potential upside of 33.06%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Gossamer Bio is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more volatility and risk, GOSS or ARQT? Gossamer Bio has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Do insiders & institutionals have more ownership in GOSS or ARQT? 81.2% of Gossamer Bio shares are owned by institutional investors. 6.7% of Gossamer Bio shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to GOSS or ARQT? In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Gossamer Bio. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 5 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.43 beat Arcutis Biotherapeutics' score of 1.04 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, GOSS or ARQT? Gossamer Bio has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M4.12-$56.53M-$0.23-9.04Arcutis Biotherapeutics$196.54M8.84-$140.04M-$1.04-14.02 SummaryGossamer Bio beats Arcutis Biotherapeutics on 10 of the 16 factors compared between the two stocks. Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOSS vs. The Competition Export to ExcelMetricGossamer BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$445.51M$3.03B$5.65B$9.53BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-9.0424.3630.2420.53Price / Sales4.12323.30449.4798.31Price / CashN/A42.5936.0158.40Price / Book16.008.278.335.74Net Income-$56.53M-$55.06M$3.25B$259.12M7 Day Performance16.85%-3.45%-2.17%-2.61%1 Month Performance69.11%13.91%7.95%8.58%1 Year Performance130.27%3.45%36.42%15.07% Gossamer Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOSSGossamer Bio4.0223 of 5 stars$2.08+6.1%$8.25+296.6%+120.1%$445.51M$114.70M-9.04180News CoverageOptions VolumeARQTArcutis Biotherapeutics2.0784 of 5 stars$14.96+0.7%$19.40+29.7%+51.4%$1.78B$196.54M-14.38150Positive NewsUpcoming EarningsTARSTarsus Pharmaceuticals1.7856 of 5 stars$41.75+0.6%$66.67+59.7%+66.9%$1.75B$182.95M-15.2950News CoveragePositive NewsUpcoming EarningsIMCRImmunocore1.4735 of 5 stars$33.94-3.5%$58.89+73.5%-16.4%$1.70B$310.20M-78.93320News CoveragePositive NewsUpcoming EarningsSDGRSchrodinger2.2364 of 5 stars$22.39+0.7%$32.75+46.3%-8.2%$1.64B$207.54M-8.51790Positive NewsUpcoming EarningsADPTAdaptive Biotechnologies2.7767 of 5 stars$10.61-1.3%$10.57-0.4%+127.0%$1.61B$189.53M-11.05790Positive NewsUpcoming EarningsEVOEvotec2.0684 of 5 stars$4.26flat$5.93+39.3%-11.5%$1.51B$862.40M0.004,827News CoverageGap UpJANXJanux Therapeutics2.439 of 5 stars$25.55-1.6%$91.89+259.6%-41.2%$1.51B$10.59M-18.7930Positive NewsUpcoming EarningsEWTXEdgewise Therapeutics1.5561 of 5 stars$14.26+1.0%$40.00+180.5%-16.5%$1.50BN/A-9.2060News CoveragePositive NewsUpcoming EarningsAnalyst ForecastABCLAbCellera Biologics2.2461 of 5 stars$4.92-3.7%$8.75+77.8%+41.5%$1.47B$28.83M-8.79500Upcoming EarningsANIPANI Pharmaceuticals3.692 of 5 stars$66.50-1.5%$78.88+18.6%-0.5%$1.44B$614.38M-52.36600Upcoming Earnings Related Companies and Tools Related Companies ARQT Competitors TARS Competitors IMCR Competitors SDGR Competitors ADPT Competitors EVO Competitors JANX Competitors EWTX Competitors ABCL Competitors ANIP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOSS) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
